Hu Y, Wang H, Zhong Y, Sun Y
Heliyon. 2024; 10(21):e38645.
PMID: 39512468
PMC: 11539248.
DOI: 10.1016/j.heliyon.2024.e38645.
Saadh M, Nabeel Mustafa A, Mustafa M, S R, Dabis H, Prasad G
Neurogenetics. 2024; 25(4):307-336.
PMID: 39266892
DOI: 10.1007/s10048-024-00779-3.
Xu H, Luo Y, Li Q, Zhu H
Front Cell Infect Microbiol. 2024; 14:1371543.
PMID: 39040602
PMC: 11260648.
DOI: 10.3389/fcimb.2024.1371543.
Soni D, Upadhayay S, Dhureja M, Arthur R, Kumar P
Inflammopharmacology. 2024; 32(5):2921-2941.
PMID: 38992324
DOI: 10.1007/s10787-024-01510-2.
Aljeradat B, Kumar D, Abdulmuizz S, Kundu M, Almealawy Y, Batarseh D
Pathophysiology. 2024; 31(2):244-268.
PMID: 38804299
PMC: 11130832.
DOI: 10.3390/pathophysiology31020019.
Microbiota, Tryptophan and Aryl Hydrocarbon Receptors as the Target Triad in Parkinson's Disease-A Narrative Review.
Iwaniak P, Owe-Larsson M, Urbanska E
Int J Mol Sci. 2024; 25(5).
PMID: 38474162
PMC: 10931713.
DOI: 10.3390/ijms25052915.
The gastrointestinal tract and Parkinson's disease.
Higinbotham A, Kilbane C
Front Cell Infect Microbiol. 2024; 13:1158986.
PMID: 38292855
PMC: 10825967.
DOI: 10.3389/fcimb.2023.1158986.
The Impact of Intestinal Microbiota and Toll-like Receptor 2 Signaling on α-Synuclein Pathology in Nontransgenic Mice Injected with α-Synuclein Preformed Fibrils.
Koyanagi Y, Kassai M, Yoneyama H
Microorganisms. 2024; 12(1).
PMID: 38257933
PMC: 10818728.
DOI: 10.3390/microorganisms12010106.
Rehabilitation for non-motor symptoms for patients with Parkinson's disease from an α-synuclein perspective: a narrative review.
Liu Z, Lemus J, Smirnova I, Liu W
Explor Neuroprotective Ther. 2023; 3(4):235-257.
PMID: 37920444
PMC: 10621781.
DOI: 10.37349/ent.2023.00049.
The Involvement of Neuroinflammation in the Onset and Progression of Parkinson's Disease.
Jurcau A, Andronie-Cioara F, Nistor-Cseppento D, Pascalau N, Rus M, Vasca E
Int J Mol Sci. 2023; 24(19).
PMID: 37834030
PMC: 10573049.
DOI: 10.3390/ijms241914582.
HMGB1 Mediates Inflammation-Induced DMT1 Increase and Dopaminergic Neurodegeneration in the Early Stage of Parkinsonism.
Liang T, Yang S, Qian C, Du L, Qian Z, Yung W
Mol Neurobiol. 2023; 61(4):2006-2020.
PMID: 37833459
DOI: 10.1007/s12035-023-03668-2.
Peripheral metabolic alterations associated with pathological manifestations of Parkinson's disease in gut-brain axis-based mouse model.
Huh E, Choi J, Lee M, Kim J, Choi Y, Ju I
Front Mol Neurosci. 2023; 16:1201073.
PMID: 37635904
PMC: 10447900.
DOI: 10.3389/fnmol.2023.1201073.
Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease.
Santos J, Oliveira L, Noleto F, Teixeira Pinheiro Gusmao C, Brito G, de Barros Viana G
Neural Regen Res. 2023; 18(12):2611-2614.
PMID: 37449597
PMC: 10358673.
DOI: 10.4103/1673-5374.373673.
Probing Gut Participation in Parkinson's Disease Pathology and Treatment via Stem Cell Therapy.
Lee J, Castelli V, Sanberg P, Borlongan C
Int J Mol Sci. 2023; 24(13).
PMID: 37445778
PMC: 10342034.
DOI: 10.3390/ijms241310600.
Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study.
Santos-Lobato B, Brito M, Pimentel A, Cavalcanti R, Del-Bel E, Tumas V
Arq Neuropsiquiatr. 2023; 81(5):460-468.
PMID: 37257466
PMC: 10232028.
DOI: 10.1055/s-0043-1768668.
Association between gut permeability, brain volume, and cognition in healthy participants and patients with schizophrenia spectrum disorder.
Scheurink T, Borkent J, Gangadin S, El Aidy S, Mandl R, Sommer I
Brain Behav. 2023; 13(6):e3011.
PMID: 37095714
PMC: 10275537.
DOI: 10.1002/brb3.3011.
Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases.
Attia M, Yahya A, Monaem N, A Sabry S
Saudi Pharm J. 2023; 31(3):417-432.
PMID: 37026045
PMC: 10071366.
DOI: 10.1016/j.jsps.2023.01.009.
Prophylactic Effect of Bovine Colostrum on Intestinal Microbiota and Behavior in Wild-Type and Zonulin Transgenic Mice.
Asbjornsdottir B, Miranda-Ribera A, Fiorentino M, Konno T, Cetinbas M, Lan J
Biomedicines. 2023; 11(1).
PMID: 36672598
PMC: 9855927.
DOI: 10.3390/biomedicines11010091.
Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Choroszy M, Litwinowicz K, Bednarz R, Roleder T, Lerman A, Toya T
Metabolites. 2022; 12(12).
PMID: 36557203
PMC: 9788186.
DOI: 10.3390/metabo12121165.
Blood-Brain Barrier Disruption and Its Involvement in Neurodevelopmental and Neurodegenerative Disorders.
Aragon-Gonzalez A, Shaw P, Ferraiuolo L
Int J Mol Sci. 2022; 23(23).
PMID: 36499600
PMC: 9737531.
DOI: 10.3390/ijms232315271.